Article Information
History
- August 4, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Elena Diago-Sempere, MD1,
- José Luis Bueno, MD2,
- Aránzazu Sancho-López, MD, PhD*,1,
- Elena Múñez Rubio, MD, PhD4,
- Ferrán Torres, MD, PhD5,
- Rosa Malo de Molina, MD6,
- Ana Fernández-Cruz (AFC), MD, PhD4,
- Isabel Salcedo de Diego, RN, PhD1,
- Ana Velasco-Iglesias, MSc, PhD. SCReN9,
- Concepción Payares-Herrera, MD, PhD1,
- Inmaculada Casas Flecha, PharmD, PhD11,
- Cristina Avendaño-Solà, MD, PhD1,
- Rafael Duarte Palomino, MD, PhD13,
- Antonio Ramos-Martínez, MD, PhD4 and
- Belén Ruiz-Antorán, MD, PhD1
- 1Clinical Pharmacology Department. Hospital Univ. Puerta de Hierro Majadahonda, Instituto de Investigación Sanitaria Puerta de Hierro - Segovia de Arana, Madrid, Spain
- 2Hemotherapy & Apheresis Units. Hematology and Hemotherapy Department. Hospital Universitario Puerta de Hierro Majadahonda
- 4Internal Medicine Department. Infectious diseases unit. Hospital Universitario Puerta de Hierro Majadahonda
- 5Clinical Pharmacology Department. Hospital Clínic Barcelona. Medical Statistics core facility - IDIBAPS
- 6Servicio de Pneumology. Hospital Universitario Puerta de Hierro Majadahonda
- 9IIS Puerta de Hierro - Segovia de Arana
- 11Flu and Respiratory Virus Unit. Centro Nacional de Microbiología, Instituto de Salud Carlos III
- 13Hematology and Hemotherapy Department. Hospital Universitario Puerta de Hierro Majadahonda
- ↵*Correspondence to:
Aránzazu Sancho-López, MD, PhD. Clinical Pharmacology Department, Hospital Universitario Puerta de Hierro Majadahonda, c/ Manuel de Falla 1, 28222, Madrid, Spain. Aranzazu.sancho{at}salud.madrid.org. Phone number: (country code +34) 911917070
Posted August 04, 2020.
Evaluation of Convalescent Plasma Versus Standard of Care for the Treatment of COVID-19 in Hospitalized Patients: study protocol for a phase 2 randomized, open-label, controlled, multicenter trial
